Navigation Links
InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring
Date:5/29/2008

American Heart Association announcement validates the critical role of

self-care in the treatment of high blood pressure

NEW YORK, May 29 /PRNewswire/ -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced its support of the new joint scientific statement from the American Heart Association, American Society of Hypertension and the Preventive Cardiovascular Nurses' Association declaring that people with hypertension should routinely monitor their blood pressure at home to help manage the disease. This is the first statement issued by the American Heart Association detailing such recommendations for home blood pressure monitor use.

"We applaud the AHA, ASH and the Preventative Cardiovascular Nurses' Association for their joint decision to support widespread use of home blood pressure monitors," said Erez Gavish, president and CEO of InterCure. "This endorsement highlights the medical community's growing reliance on patient involvement to best manage serious health conditions. Much like diabetes care, an effective hypertension treatment plan requires patient empowerment, home-based monitoring and therapy options tailored to the patient. Home blood pressure monitoring provides motivating feedback for patients to stay compliant with their treatment regimens. But, patients must also be involved in determining the therapy options best suited for them -- including medications, lifestyle modifications or clinically-proven therapeutic device options, such as RESPeRATE."

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

RESPeRATE is currently being used in more than 100,000 homes worldwide and is available at http://www.resperate.com and on store shelves including Lloyds Pharmacy in the UK and a growing number of drug stores in the United States.

About InterCure Ltd. and RESPeRATE

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Lisa Mokaba Brian Packard

Schwartz Communications InterCure, Inc.

+1-781-684-0770 +1-646-652-5800 x.7134

intercure@schwartz-pr.com bpackard@intercure.com


'/>"/>
SOURCE InterCure Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
2. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
3. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
4. Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development
5. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
6. Newly Published EPA RCRA Method 6800 Supports AIT Technology
7. National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood
8. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
11. Sirion Therapeutics Supports Ophthalmic Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):